Medical use of cannabinoids

AI Fraguas-Sánchez, AI Torres-Suárez - Drugs, 2018 - Springer
Cannabinoid receptors, endocannabinoids and the enzymes responsible for their
biosynthesis and degradation constitute the endocannabinoid system. In recent decades …

Cannabidiol (CBD) use in psychiatric disorders: A systematic review

S Bonaccorso, A Ricciardi, C Zangani, S Chiappini… - Neurotoxicology, 2019 - Elsevier
Abstract Cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC) are the most represented
phytocannabinoids in Cannabis sativa plants. However, CBD may present with a different …

Cannabinoid receptors: An update on cell signaling, pathophysiological roles and therapeutic opportunities in neurological, cardiovascular, and inflammatory …

D Haspula, MA Clark - International journal of molecular sciences, 2020 - mdpi.com
The identification of the human cannabinoid receptors and their roles in health and disease,
has been one of the most significant biochemical and pharmacological advancements to …

Endocannabinoid system in neurodegenerative disorders

BS Basavarajappa, M Shivakumar… - Journal of …, 2017 - Wiley Online Library
Most neurodegenerative disorders (NDD s) are characterized by cognitive impairment and
other neurological defects. The definite cause of and pathways underlying the progression …

New insights and potential therapeutic targeting of CB2 cannabinoid receptors in CNS disorders

BG Kibret, H Ishiguro, Y Horiuchi, ES Onaivi - International journal of …, 2022 - mdpi.com
The endocannabinoid system (ECS) is ubiquitous in most human tissues, and involved in
the regulation of mental health. Consequently, its dysregulation is associated with …

An overview of the cannabinoid type 2 receptor system and its therapeutic potential

B Bie, J Wu, JF Foss, M Naguib - Current Opinion in …, 2018 - journals.lww.com
An overview of the cannabinoid type 2 receptor system and it... : Current Opinion in
Anesthesiology An overview of the cannabinoid type 2 receptor system and its therapeutic …

Cannabinoids for treatment of Alzheimer's disease: moving toward the clinic

E Aso, I Ferrer - Frontiers in pharmacology, 2014 - frontiersin.org
The limited effectiveness of current therapies against Alzheimer's disease (AD) highlights
the need for intensifying research efforts devoted to developing new agents for preventing or …

The cannabinoid system and microglia in health and disease

SS Duffy, JP Hayes, NT Fiore, G Moalem-Taylor - Neuropharmacology, 2021 - Elsevier
Recent years have yielded significant advances in our understanding of microglia, the
immune cells of the central nervous system (CNS). Microglia are key players in CNS …

Potential and limits of cannabinoids in Alzheimer's disease therapy

G Abate, D Uberti, S Tambaro - Biology, 2021 - mdpi.com
Simple Summary This review was aimed at exploring the potentiality of drugging the
endocannabinoid system as a therapeutic option for Alzheimer's disease (AD). Recent …

Intracellular molecular targets and signaling pathways involved in antioxidative and neuroprotective effects of cannabinoids in neurodegenerative conditions

A Tadijan, I Vlašić, J Vlainić, D Đikić, N Oršolić… - Antioxidants, 2022 - mdpi.com
In the last few decades, endocannabinoids, plant-derived cannabinoids and synthetic
cannabinoids have received growing interest as treatment options in neurodegenerative …